• Most Popular
  • Most Shared

Europe approves Alcon's Azarga glaucoma treatment

Wed Dec 3, 2008 4:47am EST

Stocks

   

ZURICH, Dec 3 (Reuters) - The European Medicines Agency has approved Alcon Inc's (ACL.N) glaucoma treatment Azarga, the eye-care products maker said on Wednesday.

Stocks  |  Global Markets

Although expected, after a recommendation in September, the news boosted shares in Swiss drugmaker Novartis AG (NOVN.VX), which has bought a 25 percent stake in Alcon as a first step towards taking a majority stake from Swiss food group Nestle SA (NESN.VX).

"The launch of Azarga is good news for Alcon and Novartis," said Vontobel analyst Andrew Weiss.

The medicines agency approved Azarga for decreasing intraocular pressure in adults with open-angle glaucoma or ocular hypertension, Alcon said in a statement.

Novartis shares had risen 1.7 percent to 55.45 Swiss francs by 0942 GMT, compared with a 0.3 percent drop in the European healthcare index .SXDP. (Reporting by Sam Cage, editing by Will Waterman)



More from Reuters

Photo

GMAC to get $3.5 billion more in government aid

WASHINGTON (Reuters) - GMAC Financial Services is expected to get about $3.5 billion of additional U.S. government aid to help the troubled lender absorb mortgage losses, a financial industry source familiar with the matter said on Wednesday.

A sign informs passengers of a "High Risk of Terrorist Attack" at the departure security line at Reagan National Airport in Washington December 29, 2009.  REUTERS/Kevin Lamarque   (

Body scans are Obama's call

The Dutch are doing it. So what's taking the U.S. so long to make airport body scanners mandatory?  Full Article | Video 

People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article